142 related articles for article (PubMed ID: 33958145)
1. Molecular Biology of Bladder Cancer: Potential Implications for Therapy.
McConkey DJ
Hematol Oncol Clin North Am; 2021 Jun; 35(3):457-468. PubMed ID: 33958145
[TBL] [Abstract][Full Text] [Related]
2. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
3. Molecular Subtypes of Bladder Cancer.
McConkey DJ; Choi W
Curr Oncol Rep; 2018 Aug; 20(10):77. PubMed ID: 30128829
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.
McConkey DJ; Choi W; Ochoa A; Siefker-Radtke A; Czerniak B; Dinney CP
Hematol Oncol Clin North Am; 2015 Apr; 29(2):377-94, x-xi. PubMed ID: 25836941
[TBL] [Abstract][Full Text] [Related]
5. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
[TBL] [Abstract][Full Text] [Related]
6. Genetic subtypes of invasive bladder cancer.
McConkey DJ; Choi W; Dinney CP
Curr Opin Urol; 2015 Sep; 25(5):449-58. PubMed ID: 26218634
[TBL] [Abstract][Full Text] [Related]
7. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
Guo CC; Dadhania V; Zhang L; Majewski T; Bondaruk J; Sykulski M; Wronowska W; Gambin A; Wang Y; Zhang S; Fuentes-Mattei E; Kamat AM; Dinney C; Siefker-Radtke A; Choi W; Baggerly KA; McConkey D; Weinstein JN; Czerniak B
Eur Urol; 2016 Oct; 70(4):611-620. PubMed ID: 26988609
[TBL] [Abstract][Full Text] [Related]
8. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.
Ochoa AE; Choi W; Su X; Siefker-Radtke A; Czerniak B; Dinney C; McConkey DJ
Oncotarget; 2016 Dec; 7(49):80164-80174. PubMed ID: 27845906
[TBL] [Abstract][Full Text] [Related]
9. Novel biomarkers in bladder cancer.
Cheng ML; Iyer G
Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
[TBL] [Abstract][Full Text] [Related]
10. Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.
Seiler R; Gibb EA; Wang NQ; Oo HZ; Lam HM; van Kessel KE; Voskuilen CS; Winters B; Erho N; Takhar MM; Douglas J; Vakar-Lopez F; Crabb SJ; van Rhijn BWG; Fransen van de Putte EE; Zwarthoff EC; Thalmann GN; Davicioni E; Boormans JL; Dall'Era M; van der Heijden MS; Wright JL; Black PC
Clin Cancer Res; 2019 Aug; 25(16):5082-5093. PubMed ID: 30224344
[TBL] [Abstract][Full Text] [Related]
11. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
Choi W; Porten S; Kim S; Willis D; Plimack ER; Hoffman-Censits J; Roth B; Cheng T; Tran M; Lee IL; Melquist J; Bondaruk J; Majewski T; Zhang S; Pretzsch S; Baggerly K; Siefker-Radtke A; Czerniak B; Dinney CP; McConkey DJ
Cancer Cell; 2014 Feb; 25(2):152-65. PubMed ID: 24525232
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic Molecular Subclassification of Urothelial Carcinoma of the Bladder: Are We Finally there?
Akhtar M; Al-Bozom IA; Ben Gashir M; Taha NM
Adv Anat Pathol; 2019 Jul; 26(4):251-256. PubMed ID: 31188799
[TBL] [Abstract][Full Text] [Related]
13. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
14. Contemporary Molecular Classification of Urinary Bladder Cancer.
Goutas D; Tzortzis A; Gakiopoulou H; Vlachodimitropoulos D; Giannopoulou I; Lazaris AC
In Vivo; 2021; 35(1):75-80. PubMed ID: 33402452
[TBL] [Abstract][Full Text] [Related]
15. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
16. SIU-ICUD consultation on bladder cancer: basic science.
McConkey DJ; Lerner SP
World J Urol; 2019 Jan; 37(1):15-29. PubMed ID: 30547196
[TBL] [Abstract][Full Text] [Related]
17. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
[TBL] [Abstract][Full Text] [Related]
18. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
19. Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition.
Necchi A; Raggi D; Gallina A; Bandini M; de Jong JJ; Marandino L; Briganti A; Montorsi F; Davicioni E; Lotan Y; Gibb EA
Urol Oncol; 2021 Oct; 39(10):734.e11-734.e17. PubMed ID: 34301456
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade.
Luo H; Liu GL; Jian D; Liang DD; Li XM; Zhong L; Yang B; Jiang J; Wang D; Li MX; Lan WH; Dai N
J Immunol Res; 2022; 2022():9962397. PubMed ID: 35915657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
